Physician profile
Abby Davis
NPI 1457873044
$2,578.06
in general payments reported to CMS, 2019-2025
20 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $389 · 2023: $321 · 2024: $521 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.40 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $384.51 | 2024-2025 | Airsupra, Fasenra |
| Genentech USA, INC. | $364.44 | 2024-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $316.89 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $288.30 | 2023-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $259.96 | 2021-2025 | |
| Novo Nordisk INC | $231.65 | 2021-2023 | Rybelsus, Ozempic |
| Genzyme Corporation | $145.86 | 2024-2025 | |
| Abbvie INC. | $106.41 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $79.02 | 2025 | Dupixent |
| Lundbeck LLC | $75.00 | 2022-2024 | Vyepti, Rexulti |
| Merck Sharp & Dohme LLC | $60.22 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $47.62 | 2022-2024 | Tezspire |
| Lilly USA, LLC | $40.75 | 2021-2023 | Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $38.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.97 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $36.17 | 2022 | |
| Astellas Pharma US INC | $19.71 | 2024 | Veozah |
| Organon LLC | $16.31 | 2022 | |
| Greer Laboratories, INC. | $15.30 | 2025 | Oralair |
| Corium, LLC | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.